Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-I) in depression.

Ehrensing RH, Kastin AJ

The American journal of psychiatry1 May 1978Cited by 66 (Europe PMC)

PMID25588DOI10.1176/ajp.135.5.562PepBankPUB-00025588

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with endogenous depression, substantial improvement occurred in 5 of 8 receiving low-dose MIF-I versus 1 of 10 receiving high-dose MIF-I.
In plain wordsIn patients with depression, substantial improvement occurred in 5 of 8 receiving low-dose MIF-I versus 1 of 10 receiving high-dose MIF-I.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
IncreaseSubstantial improvement in depression
Study
n = 18
Comparator
750 mg/day MIF-I
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
75 mg/dayAs given in this study (human).
Measurements
Patients with substantial improvement
5 patients
MIF-I 75 mg/day
Patients with substantial improvement
1 patients
MIF-I 750 mg/day
Source sentences
Summary
Five of 8 patients with unipolar or bipolar endogenous depressions taking prolyl-leucyl-glycinamide (MIF-I), 75 mg/day, showed substantial improvement within a few days of beginning treatment compared with similar improvement in only 1 of 10 receiving 750 mg/day of MIF-I and only 1 of 5 patients taking placebo.
Report a problemFND-0002558802
02HumanNon-randomized trialEfficacy outcome
In patients with depression, low-dose MIF-I produced significantly greater improvement on all rating scales than high-dose MIF-I.
In plain wordsIn patients with depression, low-dose MIF-I improved all rating scales more than high-dose MIF-I.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
IncreaseDepression rating scales
Study
n = 18
Comparator
750 mg/day MIF-I
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
75 mg/dayAs given in this study (human).
Source sentences
Summary
The lower dose of MIF-I was associated with significantly greater improvement than both the higher dose and placebo on all of the rating scales used.
1 context sentence(design, population, supporting numbers)
Summary · context
Five of 8 patients with unipolar or bipolar endogenous depressions taking prolyl-leucyl-glycinamide (MIF-I), 75 mg/day, showed substantial improvement within a few days of beginning treatment compared with similar improvement in only 1 of 10 receiving 750 mg/day of MIF-I and only 1 of 5 patients taking placebo.
Report a problemFND-0002558804
03HumanNon-randomized trialEfficacy outcome
In patients with endogenous depression, substantial improvement occurred in 1 of 10 receiving high-dose MIF-I versus 1 of 5 receiving placebo.
In plain wordsIn patients with depression, substantial improvement occurred in 1 of 10 receiving high-dose MIF-I versus 1 of 5 receiving placebo.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
Direction not reportedSubstantial improvement in depression
Study
n = 15
Comparator
placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
750 mg/dayAs given in this study (human).
Measurements
Patients with substantial improvement
1 patients
MIF-I 750 mg/day
Patients with substantial improvement
1 patients
placebo
Source sentences
Summary
Five of 8 patients with unipolar or bipolar endogenous depressions taking prolyl-leucyl-glycinamide (MIF-I), 75 mg/day, showed substantial improvement within a few days of beginning treatment compared with similar improvement in only 1 of 10 receiving 750 mg/day of MIF-I and only 1 of 5 patients taking placebo.
Report a problemFND-0002558803
04HumanNon-randomized trialEfficacy outcome
In patients with endogenous depression, substantial improvement occurred in 5 of 8 receiving low-dose MIF-I versus 1 of 5 receiving placebo.
In plain wordsIn patients with depression, substantial improvement occurred in 5 of 8 receiving low-dose MIF-I versus 1 of 5 receiving placebo.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
IncreaseSubstantial improvement in depression
Study
n = 13
Comparator
placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
75 mg/dayAs given in this study (human).
Measurements
Patients with substantial improvement
5 patients
MIF-I 75 mg/day
Patients with substantial improvement
1 patients
placebo
Source sentences
Summary
Five of 8 patients with unipolar or bipolar endogenous depressions taking prolyl-leucyl-glycinamide (MIF-I), 75 mg/day, showed substantial improvement within a few days of beginning treatment compared with similar improvement in only 1 of 10 receiving 750 mg/day of MIF-I and only 1 of 5 patients taking placebo.
Report a problemFND-0002558801
05HumanNon-randomized trialEfficacy outcome
In patients with depression, low-dose MIF-I produced significantly greater improvement on all rating scales than placebo.
In plain wordsIn patients with depression, low-dose MIF-I improved all rating scales more than placebo.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
IncreaseDepression rating scales
Study
n = 13
Comparator
placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
75 mg/dayAs given in this study (human).
Source sentences
Summary
The lower dose of MIF-I was associated with significantly greater improvement than both the higher dose and placebo on all of the rating scales used.
1 context sentence(design, population, supporting numbers)
Summary · context
Five of 8 patients with unipolar or bipolar endogenous depressions taking prolyl-leucyl-glycinamide (MIF-I), 75 mg/day, showed substantial improvement within a few days of beginning treatment compared with similar improvement in only 1 of 10 receiving 750 mg/day of MIF-I and only 1 of 5 patients taking placebo.
Report a problemFND-0002558805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.